Opinion statement
African Americans have a higher burden of cardiovascular disease than white Americans, including a higher prevalence of heart failure. In addition, heart failure in African Americans conforms to a more malignant natural history. Hypertension is most often cited as the sole etiology of heart failure in African Americans. Most of the major trials of pharmacotherapy for the management of chronic heart failure have failed to include significant numbers of African-American patients. Based on the available evidence, there is no reason to withhold standard evidence-based medical therapy for heart failure. Even though there is much controversy as to the efficacy of angiotensin-converting enzyme (ACE) inhibitors and β blockers in African Americans, in the absence of definitive data they should be used. Recently, the combination of isosorbide dinitrate and hydralazine has been demonstrated to improve survival in African Americans with New York Heart Association class III and IV heart failure, and represents an adjunctive treatment option when added to standard medical therapy consisting of ACE inhibitors, β blockers, digoxin, diuretics, and aldosterone antagonists. Emerging evidence suggests that this therapy may be targeting a novel mechanism of heart failure progression (ie, nitric oxide bioavailability) found in African Americans.
Similar content being viewed by others
References and Recommended Reading
American Heart Association: African Americans and Cardiovascular Diseases Statistics Fact Sheet. Dallas, IX: American Heart Association; 2004.
Packer M, Coats AJ, Fowler MB, et al.: Effect of carvediolol on survival in severe chronic heart failure. N Engl J Med 2001, 344:1651–1658.
Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study [CONSENSUS]. The CONSENSUS Trial Study Group [no authors listed]. N Engl J Med 1987, 316:14298–1443.
Hunt SA, Baker DW, Chin MH, et al.: ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult: executive summary. A report from the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2001, 38:2101–2113.
Pitt B, Zannad F, Remme WJ, et al.: The effect of spironolactone on morbidity and mortality of patients with severe heart failure. N Engl J Med 1999, 341:709–717.
Pitt B, Remme WJ, Zannad F, et al.: Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003, 348:1309–1321.
Bardy GH, Lee KL, Mark DB, et al.: Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med 2005, 352:225–237.
Cohn JN, Tognoni G: A randomized trial of the angiotensin receptor blocker valsartan in chronic heart failure. N Engl J Med 2001, 345:1667–1675.
Yancy CW: Heart failure in African Americans: a cardiovascular enigma. J Card Fail 2000, 6:183–186.
Dries DL, Exner DV, Gersch BK, et al.: Racial differences in the outcome of left ventricular dysfunction. N Engl J Med 1999, 340:609–616.
Saunders E: Hypertension in minorities: blacks. Am J Hypertens 1995, 8(12 pt 2):115S-119S.
Flack JM, Ferdinand KC, Nasser SA: Epidemiology of hypertension and cardiovascular disease in African Americans. J Clin Hypertens 2003, 5(1 suppl 1):5–11.
Gillum RF: The epidemiology of cardiovascular disease in black Americans. N Engl J Med 1996, 335:1597–1598.
Rahman M, Douglas JG, Wright JT: Pathophysiology and treatment implications of hypertension in the African American population. Endocrinol Metab Clin North Am 1997, 26:125–144.
Levy D: Left ventricular hypertrophy risk. In Hypertension Primer. Edited by Izzo JL, et al. Dallas, TX: American Heart Association; 2003:243–246.
Turner ST, Schwartz GL, Chapman AB, et al.: C825T polymorphism of the G protein beta-3 subunit and antihypertensive response to a thiazide diuretic. Hypertension 2001, 37:739–743.
August P: TGF Beta-1 overexpressed in African American hypertensives. Proc Natl Acad Sei USA 2000, 97:3479–3484.
McNamara DM, Holubkov R, Janosko K, et al.: Pharmacogenetic interactions between beta-blocker therapy and the angiotensin-converting enzyme deletion polymorphism in patients with congestive heart failure. Circulation 2001, 103:1644–1648.
Small KM, Wagoner LE, Levin AM, et al.: Synergistic polymorphisms of beta 1 and alpha 2c adrenergic receptors and the risk of congestive heart failure. N Engl J Med 2002, 347:1135–1142.
Mason DA, Moore JD, Green SA: A gain of function polymorphism in a G-protein coupling domain of the human beta-1 adrenergic receptor. J Biol Chem 1999, 274:12670–12674.
Cohn JN, Archibald DG, Ziesche S, et al.: Effect of vasodilator therapy on mortality in chronic congestive heart failure. Results of a Veterans Administration Cooperative Study. N Engl J Med 1986, 314:1547–1552.
Cohn JN, Johnson G, Ziesche S, et al.: A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med 1991, 325:303–310.
Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD Investigators [no authors listed]. N Engl J Med 1991, 325:293–302.
Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. The SOLVD Investigators [no authors listed]. N Engl J Med 1992, 327:685–691.
A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure. The Beta-Blocker Evaluation of Survival Trial (BEST) Investigators [no authors listed]. N Engl J Med 2001, 344:1659–1667.
Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomized Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 1999, 353:2001–2007.
Packer M, Bristow MR, Cohn JN, et al.: The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. N Engl J Med 1996, 334:1349–1355.
Carson P, Fowler MB, Mohacsi P, et al.: Effect of carvedilol in black patients with severe heart failure: results of the COPERNICUS study [abstract]. Circulation 2001, 104:11–754.
Exner DV, Dries DL, Domanski MJ, et al.: Lesser response to angiotensin-converting enzyme inhibitor therapy in black as compared with white patients with left ventricular dysfunction. N Engl J Med 2001, 344:1351–1357. The first paper to establish that blacks with heart failure may have a different response to medical therapy than whites.
Dries DL, Strong MH, Cooper RS, et al.: Efficacy of angiotensin-converting enzyme inhibition in reducing progression from asymptomatic left ventricular dysfunction to symptomatic heart failure in black and white patients. J Am Coll Cardiol 2002, 40:311–317.
Bourassa MG, Gurne O, Bangdiwala SI, et al.: Natural history and patterns of current practice in heart failure. J Am Coll Cardiol 1993, 22:14A-19A.
Shekelle PG, Rich MW, Morton SC, et al.: Efficacy of angiotensin-converting enzyme inhibitors and beta-blockers in the management of left ventricular dysfunction according to race, gender, and diabetic status. A meta-analysis of major clinical trials. J Am Coll Cardiol 2003, 41:1529–1538.
Andreka P, Aiyar N, Olson LC, et al.: Bucindolol displays intrinsic sympathomimetic activity in human myocardium. Circulation 2002, 105:2429–2434.
Yancy CW, Fowler MB, Colucci WS, et al.: Race and the response to adrenergic blockade with carvedilol in patients with heart failure. N Engl J Med 2001, 344:1358–1365. Demonstrated that blacks do realize a benefit from therapy with the β-blocker carvedilol.
Pfeffer MA, Swedberg K, Granger CB, et al.: Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet 2003, 362:759–766.
Cohn JN, Tognoni G: A randomized trial of the angiotensin receptor blocker valsartan in chronic heart failure. N Engl J Med 2001, 345:1667–1675.
Pitt B, Poole-Wilson PA, Segal R, et al.: Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial—the Losartan Heart Failure Survival Study ELITE II. Lancet 2000,355:1582–1587.
Carson P, Ziesche S, Johnson G, et al.: Racial differences in response to therapy for heart failure: analysis of the vasodilator-heart failure trials. Vasodilator-Heart Failure Trial Study Group. J Card Fail 1999, 5:178–187.
Taylor AL, Ziesche S, Yancy C, et al.: Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. N Engl J Med 2004, 351:2049–2057. This study served to validate the hypothesis that blacks with heart failure derived a benefit from the combination of ISDN and HYD in addition to standard medical therapy.
Levine GM, Keaney JF, Vita JA: Cholesterol reduction in cardiovascular disease: clinical benefits and possible mechanisms. N Engl J Med 1995, 332:512–521.
Kalinowski L, Dobrucki I, Malinski T: Race-specific differences in endothelial function: predisposition of African Americans to vascular disease. Circulation 2004, 109:2511–2517.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Kamath, S.A., Yancy, C.W. Treatment of the african-american patient with congestive heart failure. Curr Treat Options Cardio Med 7, 307–315 (2005). https://doi.org/10.1007/s11936-005-0041-z
Issue Date:
DOI: https://doi.org/10.1007/s11936-005-0041-z